

FORM D
Notice of Exempt Offering of Securities

**UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.**

OMB APPROVAL
OMB Number: 3235-0076
Expires: June 30, 2012
Estimated Average burden hours per response: 4.0

1. Issuer's Identity

CIK (Filer ID Number)	Previous Name(s) <input type="checkbox"/> None	Entity Type
<input type="text" value="0001430306"/>	<input type="text" value="TAMANDARE EXPLORATIONS INC."/>	<input checked="" type="checkbox"/> Corporation
Name of Issuer		<input type="checkbox"/> Limited Partnership
<input type="text" value="Tonix Pharmaceuticals Holding Corp."/>		<input type="checkbox"/> Limited Liability Company
Jurisdiction of Incorporation/Organization		<input type="checkbox"/> General Partnership
<input type="text" value="NEVADA"/>		<input type="checkbox"/> Business Trust
Year of Incorporation/Organization		<input type="checkbox"/> Other
<input type="checkbox"/> Over Five Years Ago		
<input checked="" type="checkbox"/> Within Last Five Years (Specify Year)	<input type="text" value="2008"/>	
<input type="checkbox"/> Yet to Be Formed		

2. Principal Place of Business and Contact Information

Name of Issuer			
<input type="text" value="Tonix Pharmaceuticals Holding Corp."/>			
Street Address 1		Street Address 2	
<input type="text" value="509 MADISON AVE. - SUITE 306"/>		<input type="text"/>	
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
<input type="text" value="NEW YORK"/>	<input type="text" value="NEW YORK"/>	<input type="text" value="10022"/>	<input type="text" value="212-980-9155"/>

3. Related Persons

Last Name	First Name	Middle Name	
<input type="text" value="Lederman"/>	<input type="text" value="Seth"/>	<input type="text"/>	
Street Address 1		Street Address 2	
<input type="text" value="509 MADISON AVE., SUITE 306"/>		<input type="text"/>	
City	State/Province/Country	ZIP/Postal Code	
<input type="text" value="New York"/>	<input type="text" value="NEW YORK"/>	<input type="text" value="10022"/>	
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter

Clarification of Response (if Necessary)

Last Name

Moss

First Name

David

Middle Name

Street Address 1

509 MADISON AVE., SUITE 306

Street Address 2

City

NEW YORK

State/Province/Country

NEW YORK

ZIP/Postal Code

10022

Relationship:

Executive Officer

Director

Promoter

Clarification of Response (if Necessary)

Last Name

Selzer

First Name

Benjamin

Middle Name

Street Address 1

509 MADISON AVE., SUITE 306

Street Address 2

City

NEW YORK

State/Province/Country

NEW YORK

ZIP/Postal Code

10022

Relationship:

Executive Officer

Director

Promoter

Clarification of Response (if Necessary)

Last Name

Rosen

First Name

Rhonda

Middle Name

Street Address 1

509 MADISON AVE., SUITE 306

Street Address 2

City

NEW YORK

State/Province/Country

NEW YORK

ZIP/Postal Code

10022

Relationship:

Executive Officer

Director

Promoter

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name	
Kerridge	Susan		
Street Address 1	Street Address 2		
509 MADISON AVE., SUITE 306			
City	State/Province/Country	ZIP/Postal Code	
NEW YORK	NEW YORK	10022	
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director	<input type="checkbox"/> Promoter

Clarification of Response (if Necessary)

4. Industry Group

- | | | |
|---|--|--|
| <input type="checkbox"/> Agriculture
<input type="checkbox"/> Banking & Financial Services
<input type="checkbox"/> Commercial Banking
<input type="checkbox"/> Insurance
<input type="checkbox"/> Investing
<input type="checkbox"/> Investment Banking
<input type="checkbox"/> Pooled Investment Fund
<input type="checkbox"/> Other Banking & Financial Services | <input type="checkbox"/> Health Care
<input type="checkbox"/> Biotechnology
<input type="checkbox"/> Health Insurance
<input type="checkbox"/> Hospitals & Physicians
<input checked="" type="checkbox"/> Pharmaceuticals
<input type="checkbox"/> Other Health Care | <input type="checkbox"/> Retailing
<input type="checkbox"/> Restaurants
<input type="checkbox"/> Technology
<input type="checkbox"/> Computers
<input type="checkbox"/> Telecommunications
<input type="checkbox"/> Other Technology |
| <input type="checkbox"/> Business Services
<input type="checkbox"/> Energy
<input type="checkbox"/> Coal Mining
<input type="checkbox"/> Electric Utilities
<input type="checkbox"/> Energy Conservation
<input type="checkbox"/> Environmental Services
<input type="checkbox"/> Oil & Gas
<input type="checkbox"/> Other Energy | <input type="checkbox"/> Manufacturing
<input type="checkbox"/> Real Estate
<input type="checkbox"/> Commercial
<input type="checkbox"/> Construction
<input type="checkbox"/> REITS & Finance
<input type="checkbox"/> Residential
<input type="checkbox"/> Other Real Estate | <input type="checkbox"/> Travel
<input type="checkbox"/> Airlines & Airports
<input type="checkbox"/> Lodging & Conventions
<input type="checkbox"/> Tourism & Travel Services
<input type="checkbox"/> Other Travel
<input type="checkbox"/> Other |

5. Issuer Size

- | | |
|---|---|
| Revenue Range
<input type="checkbox"/> No Revenues
<input type="checkbox"/> \$1 - \$1,000,000
<input type="checkbox"/> \$1,000,001 - \$5,000,000
<input type="checkbox"/> \$5,000,001 - \$25,000,000
<input type="checkbox"/> \$25,000,001 - \$100,000,000
<input type="checkbox"/> Over \$100,000,000
<input checked="" type="checkbox"/> Decline to Disclose
<input type="checkbox"/> Not Applicable | Aggregate Net Asset Value Range
<input type="checkbox"/> No Aggregate Net Asset Value
<input type="checkbox"/> \$1 - \$5,000,000
<input type="checkbox"/> \$5,000,001 - \$25,000,000
<input type="checkbox"/> \$25,000,001 - \$50,000,000
<input type="checkbox"/> \$50,000,001 - \$100,000,000
<input type="checkbox"/> Over \$100,000,000
<input type="checkbox"/> Decline to Disclose
<input type="checkbox"/> Not Applicable |
|---|---|

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

- | | |
|--|--|
| <input type="checkbox"/> Rule 504(b)(1) (not (i), (ii) or (iii)) | <input type="checkbox"/> Rule 505 |
| <input type="checkbox"/> Rule 504 (b)(1)(i) | <input checked="" type="checkbox"/> Rule 506 |
| <input type="checkbox"/> Rule 504 (b)(1)(ii) | <input type="checkbox"/> Securities Act Section 4(6) |
| <input type="checkbox"/> Rule 504 (b)(1)(iii) | <input type="checkbox"/> Investment Company Act Section 3(c) |

7. Type of Filing

- New Notice Date of First Sale First Sale Yet to Occur
- Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes No

9. Type(s) of Securities Offered (select all that apply)

- | | |
|---|--|
| <input type="checkbox"/> Pooled Investment Fund Interests | <input checked="" type="checkbox"/> Equity |
| <input type="checkbox"/> Tenant-in-Common Securities | <input checked="" type="checkbox"/> Debt |
| <input type="checkbox"/> Mineral Property Securities | <input checked="" type="checkbox"/> Option, Warrant or Other Right to Acquire Another Security |
| <input checked="" type="checkbox"/> Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security | <input checked="" type="checkbox"/> Other (describe) |

Sold convertible debentures. Upon conversion or repayment, holder is entitled to receive additional consideration of a warrant or additional shares of common stock.

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary)

Private Placement was conducted in conjunction with a Reverse Merger

11. Minimum Investment

Minimum investment accepted from any outside investor \$ USD

12. Sales Compensation

Recipient	Recipient CRD Number	<input type="checkbox"/> None
<input type="text" value="WFG Investments, Inc"/>	<input type="text" value="22704"/>	
(Associated) Broker or Dealer	(Associated) Broker or Dealer	<input checked="" type="checkbox"/> None
<input checked="" type="checkbox"/> None	CRD Number	<input checked="" type="checkbox"/> None
<input type="text"/>	<input type="text"/>	
Street Address 1	Street Address 2	
<input type="text" value="2711 N. HASKELL AVE., SUITE 2900"/>	<input type="text"/>	
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="DALLAS"/>	<input type="text" value="TEXAS"/>	<input type="text" value="75204"/>
State(s) of Solicitation	<input type="checkbox"/> All States	<input type="checkbox"/> Foreign/Non-US
<input type="text" value="CALIFORNIA"/>		
<input type="text" value="NEW YORK"/>		
<input type="text" value="PENNSYLVANIA"/>		
<input type="text" value="TEXAS"/>		

13. Offering and Sales Amounts

Total Offering Amount	\$ <input type="text" value="3000000"/>	USD	<input type="checkbox"/> Indefinite
Total Amount Sold	\$ <input type="text" value="1625000"/>	USD	
Total Remaining to be Sold	\$ <input type="text" value="1375000"/>	USD	<input type="checkbox"/> Indefinite

Clarification of Response (if Necessary)

In addition, the Company is allowing holders of \$500,000 of principle face amount of old notes to exchange the old notes for secured debentures

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$ USD Estimate
Finders' Fees \$ USD Estimate

Clarification of Response (if Necessary)

A maximum of \$240,000 of sales commissions may be due and payable, of which, \$40,000 has been paid to date

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ USD Estimate

Clarification of Response (if Necessary)

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that the Issuer is not disqualified from relying on any Regulation D exemption it has identified in Item 6 above for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Tonix Pharmaceuticals Holding Corp.	/s/ Seth Lederman	Seth Lederman	President and Chief Executive Officer	2011-10-20